Global Orexin Receptor Antagonists Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Orexin Receptor Antagonists Market Research Report 2024
Orexin receptor antagonists are the type of therapeutics used in the treatment of sleep disorders, characterized by difficulties or problems with sleep onset. It either bind or inhibits the action of orexin receptor. Orexin plays a vital role in the sleep–wake cycle through a complex interplay between the monoaminergic/cholinergic (wake-promoting) and gamma-aminobutyric acidergic (sleep-promoting) neuronal systems.
According to Mr Accuracy reports’s new survey, global Orexin Receptor Antagonists market is projected to reach US$ 6887.8 million in 2029, increasing from US$ 4521 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orexin Receptor Antagonists market research.
Increased prevalence of various sleep disorders such as insomnia and parasomnias, along with rising incidence of depression and other distressing disorders are major factors driving insomnia. Expanding the Global Insomnia Market. Sleep disturbance is a common symptom of depression. For example, according to the World Health Organization (WHO), approximately 280 million people worldwide suffer from depression. Hence, the surge in the prevalence of psychotic depression across the world has led to the expansion of the insomnia market. In addition, long-term use of a drug to treat a chronic condition may cause certain adverse effects, some of which are thought to impair a patient's ability to get a good night's sleep. This means that the expansion of the market is driven by the increasing prevalence of chronic diseases such as cancer.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orexin Receptor Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Eisai Co., Ltd
Sun Pharmaceutical Industries Ltd
Novartis AG
Endo Pharmaceuticals plc
Mylan NV
Cereve Inc.
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceuticals Inc
Merck & Co.
Sanofi
Currax Pharmaceuticals LLC
Pfizer Inc.
Segment by Type
Oral
Parenteral
Insomnia
Anxious
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Orexin Receptor Antagonists report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Orexin Receptor Antagonists market is projected to reach US$ 6887.8 million in 2029, increasing from US$ 4521 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orexin Receptor Antagonists market research.
Increased prevalence of various sleep disorders such as insomnia and parasomnias, along with rising incidence of depression and other distressing disorders are major factors driving insomnia. Expanding the Global Insomnia Market. Sleep disturbance is a common symptom of depression. For example, according to the World Health Organization (WHO), approximately 280 million people worldwide suffer from depression. Hence, the surge in the prevalence of psychotic depression across the world has led to the expansion of the insomnia market. In addition, long-term use of a drug to treat a chronic condition may cause certain adverse effects, some of which are thought to impair a patient's ability to get a good night's sleep. This means that the expansion of the market is driven by the increasing prevalence of chronic diseases such as cancer.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orexin Receptor Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eisai Co., Ltd
Sun Pharmaceutical Industries Ltd
Novartis AG
Endo Pharmaceuticals plc
Mylan NV
Cereve Inc.
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceuticals Inc
Merck & Co.
Sanofi
Currax Pharmaceuticals LLC
Pfizer Inc.
Segment by Type
Oral
Parenteral
Segment by Application
Insomnia
Anxious
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Orexin Receptor Antagonists report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices